Apellis Pharmaceuticals Q4 2023 Earnings Report $27.52 -0.83 (-2.93%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Apellis Pharmaceuticals EPS ResultsActual EPS-$0.73Consensus EPS -$0.73Beat/MissMet ExpectationsOne Year Ago EPS-$1.50Apellis Pharmaceuticals Revenue ResultsActual Revenue$146.38 millionExpected Revenue$143.34 millionBeat/MissBeat by +$3.04 millionYoY Revenue Growth+545.90%Apellis Pharmaceuticals Announcement DetailsQuarterQ4 2023Date2/27/2024TimeQ4 2023 Earnings ReleaseAPLS Upcoming EarningsApellis Pharmaceuticals will be holding an earnings conference call on Friday, February 28 at 8:30 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseAPLS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Apellis Pharmaceuticals Earnings HeadlinesIs Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?February 20 at 1:04 PM | msn.comApellis announces EMA validation of Aspaveli indication extension applicationFebruary 20 at 8:03 AM | markets.businessinsider.comAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech companies are all scrambling to build hundreds of new mega data centers to keep up with the demand for training and using new AI models. But that’s where the problem is. I call it “The AI Keystone”.February 22, 2025 | Porter & Company (Ad)Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNFebruary 20 at 2:00 AM | globenewswire.comApellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In JanuaryFebruary 18, 2025 | msn.comApellis Pharmaceuticals' chief business officer sells $10,359 in stockFebruary 14, 2025 | msn.comSee More Apellis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apellis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apellis Pharmaceuticals and other key companies, straight to your email. Email Address About Apellis PharmaceuticalsApellis Pharmaceuticals (NASDAQ:APLS), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.View Apellis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
